Niagen Bioscience Inc logo NAGE - Niagen Bioscience Inc

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 5
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $10.50 DETAILS
HIGH: $11.00
LOW: $10.00
MEDIAN: $10.50
CONSENSUS: $10.50
UPSIDE: 186.89%

Stock News

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference Location: Jazz at Lincoln Center's Frederick P. Rose Hall Date: May 12, 2026 Format: Emerging Company Pavilion, a curated showcase of 8-10 select companies Management: Ozan Pamir, CFO.

May 08, 2026 04:32 AM • businesswire.com
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million. Gross margin of 63.5%, reflecting continued strength in business mix. Net income of $6.3 million, incl.

May 06, 2026 12:02 PM • businesswire.com
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #AtHomeInjection--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of its clinician-directed telehealth platform under Niagen™ Plus, enabling eligible patients in the U.S. to access prescription-only, pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride, NRCl) from home with the first-of-its-kind Niagen® At-Home Injection Kit. The launch m.

May 04, 2026 04:32 AM • businesswire.com
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a new partnership with Olympia Pharmaceuticals, a state-of-the-art U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen® (patented nicotinamide riboside, NR) for the Company's Niagen Plus™ intravenous and injectable products. Olympia Pharmaceuticals joi.

Apr 28, 2026 04:32 AM • businesswire.com
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 6, 2026.

Apr 22, 2026 04:32 AM • businesswire.com
Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy

Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy

Niagen Bioscience is transitioning from supplements to a telehealth-driven longevity platform, targeting higher margins and valuations. I rate NAGE a Strong Buy at around $6-$8 per share, projecting 40% to 75% upside as the Niagen Plus injectable launches and the recurring revenue model matures. NAGE's IP moat, strategic patent acquisition, and direct-to-consumer telehealth strategy position it for premium HealthTech multiples versus supplement peers.

Apr 15, 2026 10:27 AM • seekingalpha.com
Niagen: High-Quality Growth At A Fair Price

Niagen: High-Quality Growth At A Fair Price

Niagen's fiscal 2025 revenue growth and profitability improvement can make the stock attractive for growth-focussed investors. The company's low debt levels and relatively high amount of cash on hand allow them financial flexibility, even during market distress. Macroeconomic headwinds exist, especially low consumer confidence and high energy prices, but share issuance also poses a threat to existing shareholders.

Apr 14, 2026 09:43 PM • seekingalpha.com
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in the Company's flagship ingredient, Niagen®, now has a published United States Pharmacopeia (USP) dietary supplement ingredient monograph. This monograph reflects the scientific rigor behind Niagen and establishes.

Apr 09, 2026 04:32 AM • businesswire.com
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced OneSpaWorld (NASDAQ: OSW) as the newest Niagen Plus™ provider, engaged to offer pharmaceutical grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships. Marking Niagen Bioscience's first cruise ship clinic partnership, this collaboration brings Niagen IV to guests at sea. Rob Fried, C.

Mar 31, 2026 04:34 AM • businesswire.com
Niagen Bioscience Increases Share Repurchase Program to $20 Million

Niagen Bioscience Increases Share Repurchase Program to $20 Million

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company's previously disclosed share repurchase program (the “Program”), raising the total authorization from $10 million to $20 million of the Company's outstanding common stock. Through March 17, 2026, the Company has repurchased approxim.

Mar 19, 2026 04:32 AM • businesswire.com
Niagen Bioscience to Present at the 38th Annual ROTH Conference

Niagen Bioscience to Present at the 38th Annual ROTH Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th Annual ROTH Conference, taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California, from March 22 to 24, 2026. Niagen Bioscience CEO, Rob Fried, will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23, at.

Mar 18, 2026 04:32 AM • businesswire.com
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world. Rob Fried, CEO, Ni.

Mar 17, 2026 04:32 AM • businesswire.com
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Niagen® Skincare Innovation Lab, a new product innovation platform designed to translate the Company's leadership in NAD+ science into category-defining skincare. Debuting under the platform is Niagen NanoCloud™, a limited-release, dermatologist-tested topical skincare product powered by.

Mar 10, 2026 04:32 AM • businesswire.com
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total net sales increased 16% to $33.8 million, with Tru Niagen® sales of $27.5 million, up 21% from the prior year quarter. Gross margin increased 160 basis points to 64.1%. Net income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5.

Mar 04, 2026 11:02 AM • businesswire.com

Price Targets